% differences compared with placebo or indicated statin are based on differences of individual least square means for LDL-C, HDL-C, non-HDL-C and apoB, and on differences of individual medians or ...

Although statins are powerful lipid-lowering drugs, many patients with hypercholesterolemia do not reach current treatment goals with statin treatment. Ezetimibe the first approved direct ...

The company said it expects the data to support global regulatory submissions for the drug combination containing obicetrapib 10 mg and ezetimibe 10 mg. However, following a trading halt ...

Ezetimibe is a nonstatin low-density lipoprotein cholesterol-lowering small molecule drug. Ezetimibe is the only currently FDA-approved approved member of the of intestinal cholesterol reuptake ...

to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics. The study is expected to complete in 2027 and to enroll 300 patients.

In clinical practice, a combination of drugs is often used to treat patients with dyslipidemia who are not achieving their treatment goals. Ezetimibe reduces LDL cholesterol levels, and niacin ...